Stuart Therapeutics has collected equity financing from investors including Wisconsin Alumni Research Foundation to fund phase 2 trials for a drug aimed at dry eye disease.

Stuart Therapeutics, a US-based biopharmaceutical company focused on ophthalmic diseases, completed an $11m series A round on Tuesday featuring Wisconsin Alumni Research Foundation, the tech transfer arm of University of Wisconsin-Madison. InFocus Capital Partners led the round, which also featured Mimo Capital and Biobrit. Founded in 2017, Stuart Therapeutics is working on treatments for a…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.